
News|Articles|January 1, 2008
Sapropterin (Kuvan): Synthetic form of tetrahydrobiopterin approved for the treatment of PKU
FDA approved sapropterin on December 13, 2007, to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due ro BH4-responsive phenylketonuria (PKU).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
2
Real-World Usage of Biologics in Psoriatic Arthritis
3
Researchers discover new pathway to fight liver inflammation
4
Medicare beneficiaries are paying more for price-negotiated drugs, survey finds
5





















